HHS issues guidance on ordering commercial COVID-19 monoclonal antibody
The Department of Health and Human Services yesterday released new guidance on ordering, reporting, payment and cost-sharing for the COVID-19 monoclonal antibody therapy bebtelovimab, a treatment option for outpatients at high risk for hospitalization that begins transitioning from HHS to commercial distribution next week. Anticipating depletion of the federal government’s supply, Eli Lilly and Co. is making bebtelovimab available for purchase through AmerisourceBergen.
Related News Articles
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…